View:
Download DOC
Download PDF 


                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549
                            ------------------------
                                    FORM 8-K

                                 CURRENT REPORT

                         PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934
                            ------------------------

Date of Report (Date of earliest event reported):  March 5, 2000

                                IMMUNOGEN, INC.
             (Exact name of registrant as specified in its Charter)

Massachusetts                      0-17999                04-2726691
(State or other jurisdiction      (Commission           (IRS Employer
of incorporation)                 File Number)         Identification No.)


           128 Sidney Street, Cambridge, Massachusetts            02139
            (Address of principal executive offices)            (Zip Code)

       Registrant's telephone number, including area code: (617) 995-2500



ITEM 5. OTHER EVENTS

On March 5, 2001, ImmunoGen, Inc. ("ImmunoGen") announced the appointment of
Gregg D. Beloff as Vice President and Chief Financial Officer.

The press release announcing the appointment of Mr. Beloff is incorporated
herein by reference and filed as Exhibit 99.1 hereto.

On March 5, 2001, ImmunoGen announced that it entered into a collaboration
agreement with Millennium Pharmaceuticals, Inc.

The press release announcing the collaboration agreement with Millenium is
incorporated herein by reference and filed as Exhibit 99.2 hereto.

ITEM 7.  FINANCIAL STATEMENTS AND EXHIBITS

(c)      Exhibits.

99.1     The Registrant's Press Release dated March 5, 2001.
99.2     The Registrant's Press Release dated March 5, 2001.




                                    SIGNATURE


         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereto duly authorized.

                                               ImmunoGen, Inc.
                                               (Registrant)




Date:    March 7, 2001                         /s/ MITCHEL S. SAYARE
                                               --------------------------------
                                                   Mitchel S. Sayare
                                                   Chairman and CEO



                                                                    Exhibit 99.1

IMMUNOGEN APPOINTS NEW CHIEF FINANCIAL OFFICER

    CAMBRIDGE, Mass., March 5 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN)
today announced the appointment of Gregg D. Beloff as Vice President and Chief
Financial Officer.  Mr. Beloff was most recently a Vice President in the
Healthcare Investment Banking Group of Adams, Harkness & Hill, where he
specialized in financial and advisory transactions for biotechnology and
healthcare companies.

    "We are delighted to welcome Gregg to the executive management team at
ImmunoGen," said Mitchel Sayare, Ph.D., Chairman and CEO of ImmunoGen, Inc.
"Gregg's considerable experience with the biotechnology industry as well as his
broad financial and business credentials will make him a valuable contributor to
our future success."

    Prior to joining Adams, Harkness & Hill, Mr. Beloff was a corporate
attorney with the law firm of Gaffin & Krattenmaker.  He is a member of both
the Massachusetts and Pennsylvania Bar Associations.  Mr. Beloff received his
Master of Business Administration from Carnegie Mellon University and his
Juris Doctorate from University of Pittsburgh School of Law.

    ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for cancer
treatment. The Company has created potent tumor-activated prodrugs, consisting
of drugs coupled to monoclonal antibodies for delivery to and destruction of
cancer cells. Its lead product, huC242-DM1/SB-408075 is in two Phase I/II
clinical trials for colorectal, pancreatic and certain non-small-cell lung
cancers. The Company has collaborative arrangements with GlaxoSmithKline,
Genentech, British Biotech, Abgenix, MorphoSys, and Avalon.

    THIS PRESS RELEASE INCLUDES FORWARD-LOOKING STATEMENTS BASED ON MANAGEMENT'S
CURRENT EXPECTATIONS. FACTORS THAT COULD CAUSE FUTURE RESULTS TO DIFFER
MATERIALLY FROM SUCH EXPECTATIONS INCLUDE, BUT ARE NOT LIMITED TO: THE ABILITY
TO SECURE FUTURE FUNDING; THE SUCCESS OF THE COMPANY'S RESEARCH STRATEGY; THE
APPLICABILITY OF THE DISCOVERIES MADE THEREIN; THE DIFFICULTIES INHERENT IN THE
DEVELOPMENT OF PHARMACEUTICALS, INCLUDING UNCERTAINTIES AS TO THE TIMING AND
RESULTS OF PRECLINICAL STUDIES; DELAYED ACHIEVEMENTS OF MILESTONES; RELIANCE ON
COLLABORATORS; UNCERTAINTY AS TO WHETHER THE COMPANY'S POTENTIAL PRODUCTS WILL
SUCCEED IN ENTERING HUMAN CLINICAL TRIALS AND UNCERTAINTY AS TO THE RESULTS OF
SUCH TRIALS; UNCERTAINTY AS TO WHETHER ADEQUATE REIMBURSEMENT FOR THESE PRODUCTS
WILL EXIST FROM THE GOVERNMENT, PRIVATE HEALTHCARE INSURERS AND THIRD-PARTY
PAYORS; AND THE UNCERTAINTIES AS TO THE EXTENT OF FUTURE GOVERNMENT REGULATION
OF THE PHARMACEUTICAL BUSINESS.

     Contact:
     Mitchel Sayare, Ph.D.
     Chairman and CEO
     ImmunoGen, Inc.
     (617) 995-2500
     http://www.immunogen.com



                                                                    Exhibit 99.2

MILLENNIUM AND IMMUNOGEN FORM MULTI-PRODUCT ANTIBODY COLLABORATION

             --Alliance Focuses on Developing Enhanced and Selective
                             Oncology Therapeutics--

    CAMBRIDGE, Mass., March 5 /PRNewswire/ -- Millennium Pharmaceuticals, Inc.
(Nasdaq: MLNM) and ImmunoGen, Inc. (Nasdaq: IMGN) today announced that they have
entered into an agreement that will provide Millennium access for a period of
five years to ImmunoGen's Tumor-Activated Prodrug (TAP) technology for use with
Millennium's proprietary antibodies. Millennium will acquire a license to
utilize TAP technology in its antibody product research efforts and an option to
obtain exclusive product licenses for a restricted number of antigen targets
during the collaboration.

    The terms of this multi-year agreement call for an undisclosed up-front
technology access fee, potential milestone payments per antigen target, and
royalties on net sales of any resulting products. Millennium will be responsible
for product development, manufacturing and marketing of any products developed
through the collaboration. ImmunoGen may produce preclinical and clinical
material, at Millennium's request, for manufacturing payments. The agreement can
be renewed for one subsequent three-year period for an additional technology
access fee.

    "Combining our TAP technology with Millennium's expertise in identifying and
validating targets will accelerate the development of novel therapeutics
from the genomics revolution," said Mitchel Sayare, Ph.D., Chairman and CEO of
ImmunoGen, Inc. "We are pleased to welcome Millennium, a leader in the genomics
field, to our growing list of partners. Millennium becomes our fifth corporate
partner developing TAP products."

    "Millennium's preclinical and clinical therapeutic antibody pipeline spans a
broad spectrum of serious medical conditions such as cancer, multiple sclerosis,
inflammatory bowel disease, asthma and stroke," said John Maraganore, senior
vice president, strategic product development at Millennium. "We are very
excited to establish a relationship with ImmunoGen that will build on our
strength in oncology research and assist in our effort to generate novel, potent
and selective antibody therapies to address this unmet medical need."

    TAP TECHNOLOGY

    ImmunoGen developed its tumor-activated prodrug, or TAP, technology to
address the therapeutic need for improved cancer therapies by delivering highly
potent cytotoxic agents directly to tumor cells with minimal harm to healthy
tissue. Each TAP product is comprised of a highly potent small molecule effector
drug which is 100- to 1000-fold more potent than existing chemotherpeutics
conjugated to a tumor-targeting monoclonal antibody. The TAPs are designed to
act as prodrugs and remain nontoxic while circulating in the body, only
activated once they are inside the target cell. In preclinical studies, TAPs
have shown therapeutic efficacy and complete cures at doses with no detectable
toxicity.

    MILLENNIUM'S THERAPEUTIC ANTIBODY PIPELINE

    Millennium is a leader in the discovery and development of therapeutic
antibodies. The Company is awaiting final review from the U.S. Food and Drug
Administration of the CAMPATH(R) (alemtuzumab) investigational humanized
monoclonal antibody for treatment of patients with chronic lymphocytic leukemia
who have been treated with alkylating agents and have failed fludarabine
therapy. Millennium's pipeline also includes several other



antibodies in clinical development. In collaboration with Genentech, Inc., the
Company is conducting Phase II clinical trials with LDP-02 for Crohn's disease
and ulcerative colitis. LDP-01 is in Phase I/II clinical trials for stroke.

    Millennium has one of the most comprehensive toolkits available for
generating novel antibodies, with access to a variety of innovative and advanced
technologies. In addition to the Company's new relationship with ImmunoGen for
TAP technology, Millennium has existing relationships with Abgenix for Xenomouse
technology and Medarex, also for transgenic mouse technology. These technologies
are a powerful complement to Millennium's strong capabilities in finding novel
targets, based on broad expertise in gene discovery, functional genomics, and
disease biology. As a result, Millennium is uniquely positioned to lead the
industry in the discovery and development of antibody therapeutics.

    ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for
cancer treatment.  The Company has created potent tumor-activated prodrugs,
consisting of drugs coupled to monoclonal antibodies, for delivery to and
destruction of cancer cells. Its lead product, huC242-DM1/SB-408075 is in two
Phase I/II clinical trials for treatment of colorectal, pancreatic and certain
non-small-cell lung cancers. Besides Millennium, the Company has partnerships
with GlaxoSmithKline, Genentech, British Biotech, Abgenix, MorphoSys, and
Avalon.

    Millennium, a leading biopharmaceutical company, applies its comprehensive
and integrated science and technology platform for the discovery and development
of breakthrough therapeutic and predictive medicine products, with a goal of
delivering personalized medicine. Through the industrialization of this
gene-to-patient platform, Millennium is also striving to accelerate the process
of drug discovery and development. Headquartered in Cambridge, Massachusetts,
Millennium currently employs more than 1,300 people.

    FOR IMMUNOGEN: THIS PRESS RELEASE INCLUDES FORWARD-LOOKING STATEMENTS BASED
ON MANAGEMENT'S CURRENT EXPECTATIONS. FACTORS THAT COULD CAUSE FUTURE RESULTS TO
DIFFER MATERIALLY FROM SUCH EXPECTATIONS INCLUDE, BUT ARE NOT LIMITED TO: THE
ABILITY TO SECURE FUTURE FUNDING; THE SUCCESS OF THE COMPANY'S RESEARCH
STRATEGY; THE APPLICABILITY OF THE DISCOVERIES MADE THEREIN; THE DIFFICULTIES
INHERENT IN THE DEVELOPMENT OF PHARMACEUTICALS, INCLUDING UNCERTAINTIES AS TO
THE TIMING AND RESULTS OF PRECLINICAL STUDIES; DELAYED ACHIEVEMENTS OF
MILESTONES; RELIANCE ON COLLABORATORS; UNCERTAINTY AS TO WHETHER THE COMPANY'S
POTENTIAL PRODUCTS WILL SUCCEED IN ENTERING HUMAN CLINICAL TRIALS AND
UNCERTAINTY AS TO THE RESULTS OF SUCH TRIALS; UNCERTAINTY AS TO WHETHER ADEQUATE
REIMBURSEMENT FOR THESE PRODUCTS WILL EXIST FROM THE GOVERNMENT, PRIVATE
HEALTHCARE INSURERS AND THIRD-PARTY PAYORS; AND THE UNCERTAINTIES AS TO THE
EXTENT OF FUTURE GOVERNMENT REGULATION OF THE PHARMACEUTICAL BUSINESS.

    FOR MILLENNIUM: THIS PRESS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS,"
INCLUDING STATEMENTS ABOUT OUR GROWTH AND FUTURE OPERATING RESULTS, DISCOVERY
AND DEVELOPMENT OF PRODUCTS, POTENTIAL ACQUISITIONS, STRATEGIC ALLIANCES AND
INTELLECTUAL PROPERTY. VARIOUS RISKS MAY CAUSE MILLENNIUM'S ACTUAL RESULTS TO
DIFFER MATERIALLY, INCLUDING: ADVERSE RESULTS IN OUR DRUG DISCOVERY AND CLINICAL
DEVELOPMENT PROCESSES; FAILURE TO OBTAIN PATENT PROTECTION FOR OUR DISCOVERIES;
COMMERCIAL LIMITATIONS IMPOSED BY PATENTS OWNED OR CONTROLLED BY THIRD PARTIES;
OUR DEPENDENCE UPON STRATEGIC ALLIANCE PARTNERS TO DEVELOP AND COMMERCIALIZE
PRODUCTS AND SERVICES BASED ON OUR WORK; DIFFICULTIES OR DELAYS IN OBTAINING
REGULATORY APPROVALS TO MARKET PRODUCTS AND SERVICES RESULTING FROM OUR
DEVELOPMENT EFFORTS; AND THE REQUIREMENT FOR SUBSTANTIAL FUNDING TO



CONDUCT RESEARCH AND DEVELOPMENT AND TO EXPAND COMMERCIALIZATION ACTIVITIES. FOR
A FURTHER LIST AND DESCRIPTION OF THE RISKS AND UNCERTAINTIES WE FACE, SEE THE
REPORTS WE HAVE FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. WE DISCLAIM
ANY INTENTION OR OBLIGATION TO UPDATE OR REVISE ANY FORWARD-LOOKING STATEMENTS,
WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE.

Contacts:
     Gina Brazier (investor)                 Mitchel Sayare
     617-551-3611                            Chairman & CEO
     Maureen Suda (media)                    ImmunoGen, Inc.
     (617) 551-2959                          617-995-2500
     Millennium Pharmaceuticals, Inc.